RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM)

A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.

Study Overview

• Status: Terminated
• Conditions: Carcinoma, Small Cell Lung
• Intervention / Treatment: Combination product: RRx-001 + eLOOP Device; Drug: Cisplatin/carboplatin plus etoposide

Detailed Description

Small cell cancer (SCC), which mostly arises in the lungs but also in other parts of the body as well such as the prostate and the intestines, is one of the most aggressive forms of cancer; in fact, SCC is so aggressive that in 2012 Congress designated it a recalcitrant or difficult-to-treat cancer, along with pancreatic cancer and glioblastoma or GBM, a primary tumor of the brain, which share the terrible "distinction" of having a 5 year survival rate less than 50%.

One of the main reasons that SCC is so recalcitrant or difficult-to-treat has to do with the development of resistance. Almost all cancers (and SCC is no exception) are treated according to lines of therapy. A line of therapy is a particular course of treatment or treatment regimen. So, in SCC, the first line of treatment is a platinum doublet, with the word doublet meaning two, and consists of the double chemotherapy regimen of cisplatin or carboplatin + etoposide. Most patients initially respond well to the platinum doublet but unavoidably, as a matter of course, resistance to treatment develops and, with that development, a new treatment in second line is started. The same pattern is followed in later lines of therapy: resistance in second line leads to the start of another treatment in 3rd line, and with resistance in 3rd line, which is, unfortunately, just as inevitable, and usually happens even sooner, since the later the line of therapy the more aggressive the tumor, a 4th line treatment is started and so on and so forth until, eventually, no lines of treatment are left. The implicit or unwritten rule in cancer therapy is that once resistance occurs on a particular treatment that same treatment is never reintroduced or restarted.

RRx-001 is a form of immunotherapy that has the potential to overturn this unwritten rule by sensitizing tumors, in other words, by making them more sensitive to the platinum doublet that they received in first line. This is very important because, as previously stated, the platinum doublet is usually the most effective therapy, so it is a benefit to patients if sensitivity to the platinum doublet is restored or increased (even in cases where no response ever occurred) and now they respond as if they were in 1st line rather than in 3rd line or beyond.

In this study, which is called REPLATINUM, because patients will be reintroduced to or restarted on a platinum doublet, there is a 50% chance of receiving either RRx-001 + platinum doublet in Arm 1 or a platinum doublet without RRx-001 in Arm 2. However, patients in arm 2 whose cancer progresses or gets worse (as determined by imaging scans), have the opportunity to "cross-over" to Arm 1 and receive RRx-001 + platinum doublet until such time as their cancer progresses. In this way, all patients, even those on Arm 2, are potentially eligible to be treated with RRx-001.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Denver, Colorado, United States, 80210
      • Centura Health Research Center
  • Florida
    • Orange City, Florida, United States, 32763
      • Mid Florida Hematology and Oncology Center
    • Orlando, Florida, United States, 32804
      • AdventHealth Hematology and Oncology
    • Tampa, Florida, United States, 33612
      • H. Lee Moffitt Cancer Center & Research Institute, Inc.
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
  • Kansas
    • Topeka, Kansas, United States, 66606
      • Cotton O'Neil Clinical Research Center.Hematology & Oncology
    • Westwood, Kansas, United States, 66205
      • The University of Kansas Cancer Center
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • Norton Cancer Institute, Norton Healthcare Pavilion
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center
  • Mississippi
    • Jackson, Mississippi, United States, 39213
      • University of Mississippi Medical Center
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine - Siteman Cancer Center
  • Nebraska
    • Omaha, Nebraska, United States, 68124
      • Oncology Hematology West PC dba Nebraska Cancer Specialists
  • New Hampshire
    • Lebanon, New Hampshire, United States, 03756
      • Dartmouth-Hitchcock Medical Center
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Stephenson Cancer Center
  • Tennessee
    • Knoxville, Tennessee, United States, 37909
      • Tennessee Cancer Specialists
  • Texas
    • Houston, Texas, United States, 77090
      • Millennium Oncology
    • Tyler, Texas, United States, 75701
      • HOPE Cancer Center of East Texas
  • Utah
    • Salt Lake City, Utah, United States, 84106
      • Utah Cancer Specialist

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 18 and < 80 years
2. Prior platinum treatment is required
3. Prior treatment with a checkpoint inhibitor is required unless contraindicated. Maintenance with a checkpoint inhibitor is NOT required
4. Patient must have received at least 2 prior lines of therapy
5. Biopsy confirmation of small cell lung cancer
6. Capable of providing informed consent and complying with trial procedures
7. Measurable disease by RECIST 1.1. Measurable lesions will be confirmed by imaging (CT scan)
8. PS 0-1

Exclusion Criteria:

1. Symptomatic central nervous system metastases or neurologically unstable patients that are on increasing steroid dose.
2. The presence of another primary malignancy (excluding in situ of the cervix or basal carcinoma of the skin)
3. Treatment of SCLC with any antineoplastic agent with the exception of steroids.
4. Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, certain heart conditions, or mental illness/social situations that would limit compliance with study requirements.
5. History of an allergic reaction to previously received platinum-based regimen, or history of having to discontinue previously received platinum-based regimen secondary to toxicity (excluding hematologic toxicity)
6. Any clinical laboratory findings, which give reasonable suspicion of a disease or condition that contraindicates the use of any study medication or renders the patient at high risk from treatment
7. Uncontrolled or symptomatic pleural or pericardial effusion
8. Pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks Cisplatin/carboplatin plus etoposide (up to 4 cycles): Cisplatin or Carboplatin:Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks ORCarboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks; Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks	Combination product: RRx-001 + eLOOP Device; RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device; Drug: Cisplatin/carboplatin plus etoposide; Standard of care platinum doublet chemotherapy
Active Comparator: Arm 2; Cisplatin/carboplatin plus etoposide (up to 4 cycles): Cisplatin or Carboplatin:Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks ORCarboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks; Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks	Drug: Cisplatin/carboplatin plus etoposide; Standard of care platinum doublet chemotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival	The time from the date of randomization to disease progression (radiologic and/or symptomatic per RECIST 1.1) or death from any cause	Estimated up to 12 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	The time from randomization to death from any cause	Estimated up to 12 Months
Overall response rate	The proportion of patients with a complete response or a partial response (per RECIST 1.1)	Estimated up to 12 Months

Collaborators and Investigators

• Sponsor: EpicentRx, Inc.
• Investigators: Study Director: Bryan Oronsky, MD, PhD, EpicentRx, Inc.

Publications and helpful links

General Publications

• Oronsky B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, Varner G, Thilagar B, Brown B, Coyle A, Ferry L, Abrouk N, Oronsky A, Scribner CL, Carter CA. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019 Oct;15(30):3427-3433. doi: 10.2217/fon-2019-0317. Epub 2019 Sep 11.

Study record dates

Study Major Dates

• Study Start (Actual): December 24, 2018
• Primary Completion (Actual): August 11, 2022
• Study Completion (Actual): March 1, 2024

Study Registration Dates

• First Submitted: October 4, 2018
• First Submitted That Met QC Criteria: October 5, 2018
• First Posted (Actual): October 9, 2018

Study Record Updates

• Last Update Posted (Actual): March 26, 2024
• Last Update Submitted That Met QC Criteria: March 22, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Lung Cancer; Immunotherapy; Phase 3; Lung Neoplasms; RRx-001; Small Cell Carcinoma
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms by Histologic Type; Neoplasms; Lung Diseases; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Small Cell; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Carboplatin; Etoposide
• Other Study ID Numbers: RRx001-33

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No